Open an Account
search icon
3
NOTIFICATIONS
Best Algo trading app in India
Bigul

TORRENT PHARMACEUTICALS LTD. - 500420 - Board recommends Final Dividend

 Torrent Pharmaceuticals Ltd has informed BSE that the Board of Directors of the Company at its meeting held on May 18, 2021, inter alia, has recommended to the members a final dividend of Rs. 15/- (300%) per equity share of Rs. 5 each. The final dividend amount, if declared by the Shareholders, are proposed to be paid / dispatched on or around July 30, 2021. Earlier an interim dividend of Rs. 20/- (400%) per equity share was paid during the last quarter.
18-05-2021
Bigul

Torrent Pharmaceuticals Ltd - 500420 - Disclosure Pursuant To Regulation 30 Read With Schedule III And Regulation 33 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015.

 Outcome of Board Meeting dated 18-May-2021.
18-05-2021
Bigul

Annual report for Torrent Pharmaceuticals Ltd. for FY-2021
18-05-2021

Torrent Pharma inks pact with Eli Lilly for Covid drug Baricitinib in India

 Under royalty-free, non-exclusive deal, Torrent can make and sell baricitinib in India along with the US firm's other license partners
13-05-2021
Bigul

TORRENT PHARMACEUTICALS LTD. - 500420 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

 Torrent Pharma Enters Into Voluntary Licensing Agreement with Lilly for Baricitinib for Covid-19 in India
13-05-2021
Bigul

TORRENT PHARMACEUTICALS LTD. - 500420 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation

 We hereby inform that the Company has scheduled a teleconference with Investors / Analyst on 18th May, 2021 at 5:30 P.M. to discuss the financial performance of the Company for the quarter and year ended 31st March, 2021.
10-05-2021
Bigul

Torrent Pharmaceuticals Ltd - 500420 - Announcement under Regulation 30 (LODR)-Credit Rating

 Pursuant to Regulation 30 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, it is hereby informed that India Ratings and Research Private Limited has revised outlook to 'Positive' from 'Stable', and affirmed long term issuer rating at IND AA. The rating letter issued by the India Ratings and Research Private Limited is enclosed herewith.
06-05-2021
Bigul

TORRENT PHARMACEUTICALS LTD. - 500420 - Board to consider FY21 & Dividend on May 18, 2021

 Torrent Pharmaceuticals Ltd has informed BSE that a meeting of the Board of Directors will be held on May 18, 2021, inter alia, to consider and approve the Audited Financial Results of the Company for the year ended on March 31, 2021. In the above meeting, the Board would also consider the following: i. Payment of Final Dividend for the year 2020-21.ii. Taking enabling resolutions for raising of funds by issue of Equity Shares including Convertible Bonds / Debentures through Qualified Institutional Placement (QIP) and / or Depository Receipts or any other modes. If approved by the Board of Directors, the said item will be placed for Shareholders' approval in the ensuing Annual General Meeting.
28-04-2021
Bigul

TORRENT PHARMACEUTICALS LTD. - 500420 - Board Meeting Intimation for Intimation Of The Date Of Board Meeting Under Regulation 29 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015

 TORRENT PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 18/05/2021 ,inter alia, to consider and approve We would like to inform you that: 1. A meeting of the Board of Directors will be held on Tuesday, 18-May-21, inter alia, to consider and approve the Audited Financial Results of the Company for the year ended on 31-Mar-21. 2. In the above meeting, the Board would also consider the following: i. Payment of Final Dividend for the year 2020-21. ii. Taking enabling resolutions for raising of funds by issue of Equity Shares including Convertible Bonds / Debentures through Qualified Institutional Placement (QIP) and / or Depository Receipts or any other modes. If approved by the Board of Directors, the said item will be placed for Shareholders'' approval in the ensuing Annual General Meeting. Kindly take note of the above.
28-04-2021
Bigul

TORRENT PHARMACEUTICALS LTD. - 500420 - Format of the Annual Disclosure to be made by an entity identified as a Large Corporate

 Format of the Annual Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1 Name of Compay TORRENT PHARMACEUTICALS LTD. 2 CIN L24230GJ1972PLC002126 3 Report filed for FY 2020-21 Details of the borrowings (all figures in Rs crore) 4 Incremental borrowing done in FY(a) 895 5 Mandatory borrowing to be done through issuance of debt securities(b) = (25% of a) 224 6 Actual borrowings done through debt securities in FY(c) 395 7 Shortfall in the mandatory borrowing through debt securities, if any (d) = (b) - (c) { If the calculated value is zero or negative, write 'nil'} Nil 8 Reasons for shortfall, if any, in mandatory borrowings through debt securities Not Applicable Name of the Company Secretary :-Mahesh AgrawalDesignation :-Company Secretary Name of the Chief Financial Officer :- Sudhir Menon Designation : -Chief Financial Officer Date: 28/04/2021
28-04-2021
Next Page
Close

Let's Open Free Demat Account